Literature DB >> 25156338

Detecting reliable cognitive change in individual patients with the MATRICS Consensus Cognitive Battery.

Bradley E Gray1, Robert P McMahon1, Michael F Green2, Larry J Seidman3, Raquelle I Mesholam-Gately3, Robert S Kern2, Keith H Nuechterlein2, Richard S Keefe4, James M Gold5.   

Abstract

OBJECTIVE: Clinicians often need to evaluate the treatment response of an individual person and to know that observed change is true improvement or worsening beyond usual week-to-week changes. This paper gives clinicians tools to evaluate individual changes on the MATRICS Consensus Cognitive Battery (MCCB). We compare three different approaches: a descriptive analysis of MCCB test-retest performance with no intervention, a reliable change index (RCI) approach controlling for average practice effects, and a regression approach.
METHOD: Data were gathered as part of the MATRICS PASS study (Nuechterlein et al., 2008). A total of 159 people with schizophrenia completed the MCCB at baseline and 4weeks later. Data were analyzed using an RCI and a regression formula establishing confidence intervals.
RESULTS: The RCI and regression approaches agree within one point when baseline values are close to the sample mean. However, the regression approach offers more accurate limits for expected change at the tails of the distribution of baseline scores.
CONCLUSIONS: Although both approaches have their merits, the regression approach provides the most accurate measure of significant change across the full range of scores. As the RCI does not account for regression to the mean and has confidence limits that remain constant across baseline scores, the RCI approach effectively gives narrower confidence limits around an inaccurately predicted average change value. Further, despite the high test-retest reliability of the MCCB, a change in an individual's score must be relatively large to be confident that it is beyond normal month-to-month variation.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  MATRICS; MCCB; Regression; Reliable change; Schizophrenia

Mesh:

Year:  2014        PMID: 25156338      PMCID: PMC4469996          DOI: 10.1016/j.schres.2014.07.032

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  11 in total

1.  Regression equations in clinical neuropsychology: an evaluation of statistical methods for comparing predicted and obtained scores.

Authors:  J R Crawford; D C Howell
Journal:  J Clin Exp Neuropsychol       Date:  1998-10       Impact factor: 2.475

2.  Detecting significant change in neuropsychological test performance: a comparison of four models.

Authors:  N R Temkin; R K Heaton; I Grant; S S Dikmen
Journal:  J Int Neuropsychol Soc       Date:  1999-05       Impact factor: 2.892

3.  Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.

Authors:  Daniel C Javitt; Robert W Buchanan; Richard S E Keefe; Robert Kern; Robert P McMahon; Michael F Green; Jeffrey Lieberman; Donald C Goff; John G Csernansky; Joseph P McEvoy; Fred Jarskog; Larry J Seidman; James M Gold; David Kimhy; Karen S Nolan; Deanna S Barch; M Patricia Ball; James Robinson; Stephen R Marder
Journal:  Schizophr Res       Date:  2011-12-12       Impact factor: 4.939

4.  Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.

Authors:  Richard S E Keefe; Kolleen Hurley Fox; Philip D Harvey; Josephine Cucchiaro; Cynthia Siu; Antony Loebel
Journal:  Schizophr Res       Date:  2010-12-31       Impact factor: 4.939

5.  Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.

Authors:  Michael F Green; Keith H Nuechterlein; Robert S Kern; Lyle E Baade; Wayne S Fenton; James M Gold; Richard S E Keefe; Raquelle Mesholam-Gately; Larry J Seidman; Ellen Stover; Stephen R Marder
Journal:  Am J Psychiatry       Date:  2008-01-02       Impact factor: 18.112

6.  The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.

Authors:  Keith H Nuechterlein; Michael F Green; Robert S Kern; Lyle E Baade; Deanna M Barch; Jonathan D Cohen; Susan Essock; Wayne S Fenton; Frederick J Frese; James M Gold; Terry Goldberg; Robert K Heaton; Richard S E Keefe; Helena Kraemer; Raquelle Mesholam-Gately; Larry J Seidman; Ellen Stover; Daniel R Weinberger; Alexander S Young; Steven Zalcman; Stephen R Marder
Journal:  Am J Psychiatry       Date:  2008-01-02       Impact factor: 18.112

7.  The effect of screening on some pretest-posttest test variances.

Authors:  D A Follmann
Journal:  Biometrics       Date:  1991-06       Impact factor: 2.571

8.  A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.

Authors:  Robert W Buchanan; Richard S E Keefe; Jeffrey A Lieberman; Deanna M Barch; John G Csernansky; Donald C Goff; James M Gold; Michael F Green; L Fredrik Jarskog; Daniel C Javitt; David Kimhy; Michael S Kraus; Joseph P McEvoy; Raquelle I Mesholam-Gately; Larry J Seidman; M Patricia Ball; Robert P McMahon; Robert S Kern; James Robinson; Stephen R Marder
Journal:  Biol Psychiatry       Date:  2010-12-08       Impact factor: 13.382

9.  Detecting change: A comparison of three neuropsychological methods, using normal and clinical samples.

Authors:  R K Heaton; N Temkin; S Dikmen; N Avitable; M J Taylor; T D Marcotte; I Grant
Journal:  Arch Clin Neuropsychol       Date:  2001-01       Impact factor: 2.813

10.  Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?

Authors:  Terry E Goldberg; Robert S Goldman; Katherine E Burdick; Anil K Malhotra; Todd Lencz; Raman C Patel; Margaret G Woerner; Nina R Schooler; John M Kane; Delbert G Robinson
Journal:  Arch Gen Psychiatry       Date:  2007-10
View more
  7 in total

1.  High-intensity interval training and active video gaming improve neurocognition in schizophrenia: a randomized controlled trial.

Authors:  Gry Bang-Kittilsen; Jens Egeland; Tom Langerud Holmen; Therese Torgersen Bigseth; Eivind Andersen; Jon Mordal; Pål Ulleberg; John Abel Engh
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-11-06       Impact factor: 5.270

2.  Domain-specific cognitive course in schizophrenia: Group- and individual-level changes over 10 years.

Authors:  Camilla Bärthel Flaaten; Ingrid Melle; Thomas Bjella; Magnus Johan Engen; Gina Åsbø; Kristin Fjelnseth Wold; Line Widing; Erlend Gardsjord; Linn-Sofie Sæther; Merete Glenne Øie; Siv Hege Lyngstad; Beathe Haatveit; Carmen Simonsen; Torill Ueland
Journal:  Schizophr Res Cogn       Date:  2022-06-22

3.  Individual trajectories of cognitive performance in first episode psychosis: a 2-year follow-up study.

Authors:  A M Sánchez-Torres; L Moreno-Izco; R Lorente-Omeñaca; B Cabrera; A Lobo; A M González-Pinto; J Merchán-Naranjo; I Corripio; E Vieta; E de la Serna; A Butjosa; F Contreras; S Sarró; G Mezquida; M Ribeiro; M Bernardo; M J Cuesta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-11-21       Impact factor: 5.270

4.  The Early Psychosis Intervention Center (EPICENTER): development and six-month outcomes of an American first-episode psychosis clinical service.

Authors:  Nicholas J K Breitborde; Emily K Bell; David Dawley; Cindy Woolverton; Alan Ceaser; Allison C Waters; Spencer C Dawson; Andrew W Bismark; Angelina J Polsinelli; Lisa Bartolomeo; Jessica Simmons; Beth Bernstein; Patricia Harrison-Monroe
Journal:  BMC Psychiatry       Date:  2015-10-28       Impact factor: 3.630

5.  NRXN1 is associated with enlargement of the temporal horns of the lateral ventricles in psychosis.

Authors:  Ney Alliey-Rodriguez; Tamar A Grey; Rebecca Shafee; Huma Asif; Olivia Lutz; Nicolas R Bolo; Jaya Padmanabhan; Neeraj Tandon; Madeline Klinger; Katherine Reis; Jonathan Spring; Lucas Coppes; Victor Zeng; Rachal R Hegde; Dung T Hoang; Deepthi Bannai; Uzma Nawaz; Philip Henson; Siyuan Liu; Diane Gage; Steven McCarroll; Jeffrey R Bishop; Scot Hill; James L Reilly; Rebekka Lencer; Brett A Clementz; Peter Buckley; David C Glahn; Shashwath A Meda; Balaji Narayanan; Godfrey Pearlson; Matcheri S Keshavan; Elena I Ivleva; Carol Tamminga; John A Sweeney; David Curtis; Judith A Badner; Sarah Keedy; Judith Rapoport; Chunyu Liu; Elliot S Gershon
Journal:  Transl Psychiatry       Date:  2019-09-17       Impact factor: 6.222

6.  PROMIS scores of patients undergoing neoadjuvant and adjuvant radiation therapy for surgically excised soft tissue sarcoma.

Authors:  T M Moon; R Furdock; L Rhea; M Pergolotti; C Cipriano; M B Spraker
Journal:  Clin Transl Radiat Oncol       Date:  2021-08-29

7.  Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia.

Authors:  Richard S E Keefe; George M Haig; Stephen R Marder; Philip D Harvey; Eduardo Dunayevich; Alice Medalia; Michael Davidson; Ilise Lombardo; Christopher R Bowie; Robert W Buchanan; Dragana Bugarski-Kirola; William T Carpenter; John T Csernansky; Pedro L Dago; Dante M Durand; Frederick J Frese; Donald C Goff; James M Gold; Christine I Hooker; Alex Kopelowicz; Antony Loebel; Susan R McGurk; Lewis A Opler; Amy E Pinkham; Robert G Stern
Journal:  Schizophr Bull       Date:  2015-09-11       Impact factor: 9.306

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.